secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLUS THERAPEUTICS, INC. (PSTV)
CIK:        0001095981
Form:       8-K
Filed at:   2024-03-05T23:59:59+00:00
Accession:  0000950170-24-025866
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Plus Therapeutics reports FY2023 net loss $13.3M; cash $8.6M; ReSPECT-LM advances to Cohort 5
--------------------------------------------------------------------------------

- Net loss $(13.3)M ($4.24 per share) vs $(20.3)M ($11.58 per share) in 2022; operating loss improved to $13.3M from $19.7M.
- Cash at Dec 31, 2023 was $8.6M, down from $18.1M; runway forecast into 2H 2025.
- Enrolled 5th of 7 dosing cohorts in ReSPECT-LM Phase 1 trial for leptomeningeal metastases; orphan drug designation granted for breast cancer LM.
- Received $3.3M advance from CPRIT grant ($17.6M total); total grant revenue recognized $4.9M in 2023.
- Plans FDA meetings in 2024 to align on pivotal trial design for LM and GBM; registrational trial target 1H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1095981/000095017024025866/0000950170-24-025866-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1095981/000095017024025866/pstv-20240305.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-025866

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer